Imaging AI in California

Darmiyan, Inc. is a neuroscience-driven AI and medical imaging software company developing diagnostic tools for early detection and monitoring of neurodegenerative diseases, specifically Alzheimer's disease and dementia. The company's core technology leverages over four decades of pioneering brain research combined with advanced machine learning and medical image processing to analyze cellular-level changes in brain MRI scans. BrainSee, Darmiyan's flagship FDA De Novo-approved software, utilizes proprietary algorithms to quantify microscopic tissue architecture changes (voxel-level analysis) within standard clinical-grade MRI scans, enabling non-invasive early disease detection and patient-specific monitoring of therapeutic responses. The company targets three primary markets: early Alzheimer's detection in at-risk populations, objective measurement of patient response to interventions, and biomarker development for pharmaceutical drug development programs. Darmiyan's technology is designed around four core pillars: high diagnostic accuracy, non-invasiveness, seamless integration with existing MRI infrastructure, and global accessibility. The platform operates without requiring specialized imaging hardware, positioning it for broad adoption across healthcare settings. FDA Breakthrough Designation was granted to BrainSee for its potential to improve treatment of Alzheimer's disease. Third-party clinical validation has been completed in the US and Canada by independent research investigators. The company serves healthcare providers, pharmaceutical development teams, academic medical centers, and clinical research organizations pursuing precision brain health screening and monitoring solutions.

identifeye HEALTH Inc. develops a next-generation retinal imaging platform designed for point-of-care ophthalmologic and systemic health screening. The company's core offering is an automated, intuitive platform that captures high-quality fundus images with streamlined workflow integration into busy healthcare environments. The retinal imaging system leverages non-invasive visualization of the retina—the only location in the human body where nerves and blood vessels are directly visible without intervention—to provide personalized health insights. identifeye HEALTH is developing a suite of AI-powered screening and monitoring tools to unlock advanced clinical diagnostics at the point-of-care. The platform targets healthcare facilities seeking efficient fundus imaging capture and early disease detection. The company has received recognition in digital health and medtech publications, indicating emerging market presence and clinical validation interest.

JLK Inc is a medical artificial intelligence company headquartered in Santa Clara, CA, specializing in AI-driven diagnostic solutions for neurological and oncological conditions. The company develops MEDIHUB, a comprehensive AI-based platform suite that processes multiple imaging modalities—including CT, CTA, MRI, MRA, digital pathology, endoscopy, X-ray, and mammography—to support clinical decision-making across stroke management and cancer detection. The MEDIHUB Stroke platform addresses the complete care continuum from acute-phase intervention to chronic-phase prognostic prediction, with integrated mobile applications enabling rapid diagnosis and treatment planning. MEDIHUB also covers dementia assessment and brain aging analysis, plus detection and analysis of 12 cancer types including prostate, breast, gastric, and colorectal cancers. JLK positions its technology as a workflow optimization tool designed to reduce door-to-treatment time in stroke management and improve patient outcomes through early, accurate disease detection. The company targets hospital systems, imaging centers, and diagnostic facilities requiring AI-powered image analysis and clinical decision support. No specific FDA 510(k) clearances, ISO certifications, or regulatory credentials are mentioned on the website.

QT Imaging Holdings, Inc. (QT Ultrasound LLC) is an FDA-cleared medical technology company specializing in automated breast imaging using quantitative transmission (QT) ultrasound technology. The flagship QTI Breast Acoustic CT™ Scanner delivers high-resolution 3D breast imaging without ionizing radiation or compression, utilizing low-frequency sound waves and AI-powered lesion classification. Designed for initial evaluation of asymptomatic high-risk women and those with dense breast tissue, the system combines advanced hardware with cloud-based image analytics and tissue biomarker analysis. The platform integrates with multimodality imaging workflows via the QTI Imaging-Olea Viewer and offers non-operator-dependent, safe alternatives to mammography, tomosynthesis, and MRI for breast cancer screening and diagnosis.

Dicom Systems Inc. is an enterprise medical imaging software company specializing in vendor-neutral DICOM routing, image management, and digital pathology workflows. The company operates the Unifier® platform, which processes 124 billion medical images (548 million studies) annually across 650+ deployed sites worldwide. Unifier integrates DICOM routing, PACS interoperability, archiving, de-identification, and AI workflow orchestration into a unified enterprise imaging infrastructure. The platform supports radiology, teleradiology, and digital pathology environments across on-premise, cloud, and hybrid deployments. Core capabilities include real-time DICOM routing with metadata-driven rules, vendor-neutral archiving and VNA functionality, HIPAA/GDPR-compliant de-identification at metadata and pixel levels, HL7/DICOM data normalization, and AI Conductor for automated algorithm integration and prioritized study routing. The company serves hospitals, health systems, radiology providers, government/public health organizations, academic medical centers, specialized imaging providers, and clinical research organizations. Unifier achieves high-throughput performance (800,000+ studies/day, 85,735 slides/day) and supports enterprise-scale digital pathology whole-slide imaging workflows. The platform emphasizes workflow optimization, latency reduction, interoperability across multi-vendor environments, and secure data governance for clinical research and migration initiatives.

Sirona Medical is a cloud-native software company specializing in radiology image management, diagnostic reporting, and AI-driven workflows. The company develops Rad OS™, an integrated platform that unifies PACS (Picture Archiving and Communication System), reporting, viewer, and worklist functionality into a single browser-based operating system for radiologists. The platform leverages AWS cloud infrastructure to enable radiologists to read studies from anywhere without legacy on-premise servers or software downloads. Sirona's core offering includes: (1) PACS Archive—a fully managed AWS-backed system with 99.99% availability and no maintenance overhead; (2) Pixel-Powered Reporter—an AI-driven reporting engine using agentic AI, proprietary NLP, and a radiology-specific large language model (LLM) to auto-generate impressions and pre-draft structured reports; (3) Integrated Viewer with patented Ontology classification that organizes studies and auto-places measurements into reports; and (4) Unified Worklist aggregating multiple sites and systems with embedded AI for context prioritization. The company integrates all clinical data feeds (DICOM, HL7, speech) and employs multimodal AI capabilities including speech-to-action agentic agents that execute workflow tasks. Pixel-to-report functionality (auto-placement of findings into appropriate report sections) is noted as undergoing regulatory review. Sirona operates a business model serving radiology practices, imaging centers, and health systems. The company has raised $110M since inception, has 30+ contracted customers across 110+ integrated sites, and maintains partnerships with AI vendors (RevealDX, Koios) for specialized diagnostic capabilities such as lung cancer screening. The platform supports remote access via SpaceX Starlink and operates with HIPAA compliance on AWS infrastructure.

Bio SB, Inc. is an FDA-registered and ISO 13485:2016 certified biotechnology manufacturer specializing in research, development, production, and distribution of antibodies and detection systems for molecular pathology. The company offers IVD validated monoclonal antibodies (rabbit and mouse), detection systems (ImmunoDetector, PolyDetector), and in situ hybridization technologies (FISH, CISH) for immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and related diagnostic applications. Bio SB also manufactures automated staining equipment (TintoStainer Plus, TintoDetector) and tissue/cell line microarrays for cancer diagnostics, microbiology, immunology, and genetics research. The company serves biomedical laboratories, research institutions, and clinical settings globally, manufactured to FDA QSR 21 CFR Part 820 cGMP and CE IVD standards.

Liferiver Bio-Tech is a diagnostics company specializing in nucleic acid detection and molecular testing solutions. The company manufactures PCR-based diagnostic kits, automated extraction systems, and reagents for infectious disease detection across multiple pathogen categories including respiratory pathogens, sexually transmitted infections, hepatitis viruses, tumor markers, zoonotic diseases, and gastrointestinal pathogens. Primary product lines include the AutraMic mini4800 Plus automated workstation for nucleic acid extraction and PCR testing, ChinKing mini automation solution, and comprehensive real-time PCR kit portfolios. Liferiver's monkeypox detection kits are marketed for qualitative detection of monkeypox virus DNA in suspected cases. The company offers nucleic acid isolation kits (centrifuge column and AutoEX36 E variants), extraction consumables, and multiplex PCR reagents. Liferiver serves clinical laboratories and diagnostic centers globally, with product deployment across infectious disease surveillance, outbreak response, and routine patient testing. The company demonstrates regulatory compliance capabilities with product authentication support and regulatory documentation resources on their site. Manufacturing and distribution infrastructure supports both US/Canada markets and international territories, with animal-related products excluded from US sales per disclaimer.

CorTechs Labs is a SaaS-based medical imaging software company specializing in AI-powered quantitative analysis of brain and oncological imaging. The company develops advanced algorithms for automated brain segmentation, volumetric analysis, and lesion quantification across MRI, CT, and PET modalities. Their solutions enable clinicians to detect and monitor neurodegenerative diseases (dementia, Alzheimer's, multiple sclerosis), brain tumors, and prostate cancer with improved diagnostic confidence and efficiency. CorTechs' flagship NeuroQuant® platform has processed over 2 million brain scans across 1,500+ medical institutions in 44 countries, providing radiologists with rapid, objective measurements for disease progression tracking and comparative analysis against normative databases. The company also offers OnQ™ Prostate for prostate MRI analysis and specialized tools for lesion surveillance and post-operative assessment. Solutions integrate with major OEM imaging platforms (GE, Siemens, Philips, Canon) and are supported by Category III CPT codes for reimbursement.

Ziosoft USA Inc is a medical imaging software company specializing in advanced visualization and quantitative analysis solutions. Since 1998, the company has developed cutting-edge 3D/4D visualization and analysis platforms serving healthcare professionals and research institutions globally. The primary product is Ziostation2, a comprehensive multi-modality and multi-specialty imaging analysis platform designed to handle complex clinical demands across diverse medical specialties. Ziostation2 integrates advanced visualization capabilities with quantitative analysis tools, enabling radiologists and clinicians to process large imaging datasets with high-speed performance and superior image transmission reliability. The platform supports scalable infrastructure that integrates with existing hospital systems to consolidate workflows and reduce operational costs. Product offerings include Advanced Visualization modules, REVORAS (PhyZiodynamics), and Zioflex (Universal Image Access), which collectively address enterprise-level visualization needs. The company emphasizes customizable workflows, extensive clinical protocols, and superior computational performance. Ziosoft targets hospitals, imaging centers, and research facilities requiring sophisticated post-processing and analysis of medical imaging data across CT, MRI, ultrasound, and other modalities. The software is designed for both clinical diagnostic use and scientific research applications.

SOTA Cloud is a cloud-based dental imaging software platform that integrates diagnostic imaging, practice management, and clinical collaboration tools. Founded as a spinoff from SOTA Imaging in 2021, the company provides FDA-cleared imaging and diagnostic solutions including AI oral disease detection (Pearl), CBCT imaging with multiplanar reconstruction, and support for 3D intraoral scans. The platform integrates seamlessly with virtually all intraoral sensors, panoramic/cephalometric machines, and 20+ practice management systems (e.g., CareStack, Eaglesoft, Apertyx). Key features include browser-based image capture and viewing with unlimited cloud storage, AI-powered referral letter generation, secure file sharing with built-in DICOM dataset attachment, and comprehensive practice analytics for exam tracking, staff performance, and device monitoring. SOTA Cloud serves independent practices, group practices, dental service organizations (DSOs), and educational institutions, with emphasis on vendor independence, compliance, and multi-location workflow automation.

Canon Medical Systems USA, Inc. is a major US manufacturer and distributor of advanced diagnostic and medical imaging equipment, serving hospitals, imaging centers, and specialized clinical environments. The company manufactures a comprehensive portfolio spanning computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, x-ray, angiography, molecular imaging (PET-CT), and ophthalmology systems. Primary CT product lines include the Aquilion ONE / INSIGHT Edition and Aquilion Serve SP series, featuring Deep Learning Reconstruction and photon counting technology. MRI offerings comprise the Vantage Galan 3T / Supreme Edition and Vantage Fortian 1.5T systems with Advanced Intelligent Clear-IQ Engine (AiCE) technology. Ultrasound products include the Aplio i-series / Prism Edition and Aplio flex systems. X-ray equipment ranges from the Adora DRFi hybrid system to mobile units like Mobirex i9. Angiography systems include the Alphenix 4D CT platform for interventional cardiology, oncology, and neuro-intervention. Molecular imaging division offers Cartesion Prime SP Digital TOF PET-CT. Eye care devices include OCT and retinal imaging systems. The company operates a robust healthcare IT division offering PACS, AI-assisted imaging, and clinical decision support software. Canon Medical emphasizes dose reduction, AI-driven workflow automation, and clinical applications across stroke, prostate, women's health, sports medicine, and ASC/OBL markets. FDA 510(k) cleared products; multiple regulatory clearances throughout 2025. Comprehensive service and support infrastructure includes Customer Solutions Center, service agreements, parts ordering, EnVision 360 monitoring, cybersecurity solutions, and training via Canon Medical Academy USA.

Pulmonx Corporation is a global medical technology company headquartered in Redwood City, California, with operations in Neuchâtel, Switzerland, founded in 1995. The company specializes in minimally invasive bronchoscopic interventions for severe emphysema and chronic obstructive pulmonary disease (COPD). Pulmonx pioneered bronchoscopic lung volume reduction (BLVR) technology and has established itself as a leader in interventional pulmonology solutions for patients unsuitable for or unresponsive to surgical intervention. The company's flagship product portfolio includes the Zephyr® Endobronchial Valve, a clinically validated device that reduces lung hyperinflation by occluding diseased airways, demonstrating significant improvements in lung function (FEV1), exercise capacity, and quality of life across multiple randomized controlled trials. The Chartis® Pulmonary Assessment System provides collateral ventilation assessment to optimize patient selection and treatment planning. The LungTraX Platform delivers cloud-based quantitative CT analysis for personalized treatment planning. Pulmonx's devices are FDA-approved and supported by extensive clinical evidence across four major randomized controlled trials, with over 100 published clinical summaries. The company maintains a global network of treating physicians and assessment centers, with rigorous credentialing criteria including specialized training, hands-on competency, and outcomes monitoring.

Viz.ai is an AI-powered care coordination platform that leverages over 50 FDA-cleared algorithms to analyze medical imaging data and detect suspected diseases in real time. The company's flagship product, Viz.ai One®, autodetects conditions across multiple therapeutic areas including neurovascular disease, vascular conditions, cardiac imaging, trauma, and general radiology. The platform integrates specialized suites—Viz Neuro, Viz Cardio, Viz Vascular, Viz Trauma, and Viz Radiology—designed to accelerate diagnosis, streamline clinical workflows, and facilitate faster treatment decisions in acute care settings. Deployed in over 1,700 hospitals and health systems across the U.S. and Europe, Viz.ai's technology processes CT scans, EKGs, echocardiograms, and other imaging modalities to deliver automated assessments and real-time alerts to clinicians via mobile and desktop devices. The platform also supports life sciences partnerships with pharmaceutical and medical device companies for clinical trial optimization and disease-specific research applications.

Pearl Inc. is a dental AI software company providing FDA-cleared diagnostic and practice management tools for dental clinics globally. The company develops artificial intelligence solutions that analyze 2D X-rays and 3D CBCT imagery to support radiologic diagnosis, enhance patient communication, optimize clinical workflows, and improve revenue cycle management. Pearl's core products include Second Opinion (pathology detection in dental X-rays), Second Opinion 3D (CBCT analysis for specialists and general dentists), Practice Intelligence (data analytics for practice growth), Precheck (automated insurance verification and cost estimation), Calibrate (AI-guided clinical training), and Pearl Voice (ambient voice AI for clinical documentation and periodontal charting). The platform integrates with 40+ dental practice management and imaging systems including Eaglesoft, Dentrix Ascend, Dolphin, Carestream, Romexis, Vatech, Apteryx, and others. Pearl serves over 23,000 dental practices across 120+ countries and holds 26+ regulatory clearances. The company is FDA-cleared for diagnostic support workflows and claims to help practices increase treatment acceptance by 30%, detect 37% more disease, deliver 24% more care, save 20+ hours per week in operational time, and boost monthly production by $30K. Target markets include general dental practices, specialists, dental schools, and DSO networks. Pearl positions itself as dentistry's leading AI platform with emphasis on clinical validation, transparent reporting, and seamless EHR/imaging system integration.

Eyenuk is a global AI-driven digital health company specializing in autonomous eye screening technology for detection of diabetic retinopathy, age-related macular degeneration, and glaucoma. The company develops deep learning algorithms for retinal image analysis and has pioneered the EyeArt® AI Eye Screening System, the world's most extensively validated autonomous AI tool for diabetic retinopathy detection, tested on over half a million patient visits and 2 million images in real-world clinical settings. EyeArt requires no expert human grading, dilation, or specialist interpretation—enabling complete imaging, grading, and reporting within a single office visit in under 60 seconds. The system integrates a fundus camera with proprietary deep learning and image quality assessment algorithms that robustly detect disease presence and extent per internationally recognized clinical scales. EyeArt holds FDA 510(k) clearance for autonomous diabetic retinopathy detection across multiple camera platforms, EU CE marking (Class IIb MDR certification), and Health Canada licensure. Recent validation studies demonstrate 91.3% sensitivity and 91.1% specificity for referable DR, and 98.5% sensitivity for vision-threatening DR, across 100,000+ consecutive patient encounters. The platform empowers primary care physicians, endocrinologists, nurses, and technicians to perform point-of-care screening without subspecialty training, addressing the critical gap in annual diabetic retinopathy screening compliance. Eyenuk collaborates with major research institutions, health systems (including NHS deployment), and safety-net providers. Additional products under development include EyeMark™ (progression tracking), EyeArt™ AMD, EyeArt™ Glaucoma, and EyeRead™ UWF (ultra-widefield lesion analysis).

Coreline Soft Co., Ltd. is a South Korean medical AI software developer specializing in diagnostic imaging analysis and clinical decision support. The company develops the AVIEW platform, a suite of AI-powered software solutions for detecting and analyzing pulmonary and neurological conditions from CT and other medical imaging modalities. Core product lines include AVIEW LCS Plus (lung nodule, emphysema, and coronary artery calcification detection), AVIEW LCS (lung nodule detection and characterization), AVIEW COPD (chronic obstructive pulmonary disease analysis), AVIEW CAC (coronary artery calcification scoring), AVIEW Lung Texture (pulmonary pattern analysis), AVIEW NeuroCAD (intracranial hemorrhage detection and diagnosis support), AVIEW ILA (interstitial lung abnormality analysis), AVIEW Modeler (3D medical image modeling and 3D printing), AVIEW RT ACS (organ auto-segmentation), and data management solutions including pseudonymization servers. The company serves healthcare facilities globally, with established partnerships in Europe, North America, and Asia-Pacific for lung cancer screening programs and clinical research. Solutions integrate with existing hospital PACS and clinical workflows to automate image interpretation and provide radiologists with quantitative diagnostic support. The company publishes peer-reviewed clinical research demonstrating product utility and has exceeded 500 clinical publications. Regulatory approvals and certifications are indicated by deployment in hospitals across multiple jurisdictions, though specific FDA 510(k) or CE mark designations are not explicitly stated in available content.

4DMedical Limited develops advanced software for functional lung imaging and analysis. The company specializes in extracting quantified lung function data from standard imaging modalities (X-ray and CT) to enable non-invasive diagnosis and treatment planning. Core products include CT:VQ™ (FDA-cleared non-contrast CT ventilation/perfusion imaging), CT Lung Volume Analysis System (CT-LVAS), Lung Density Analysis, and XV Lung Volume Analysis. These solutions are designed for pulmonology, thoracic surgery, and VA healthcare settings, particularly for patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease, and veterans exposed to airborne toxins. The company's XV Technology platform provides breakthrough functional lung imaging capabilities. 4DMedical has obtained FDA clearance for CT:VQ™ and CE Mark approval for European commercialization as of March 2026. The software integrates with existing hospital imaging infrastructure and enables clinicians to quantify regional lung ventilation and perfusion without contrast agents. Target markets include academic medical centers, thoracic surgery programs, VA hospitals, and pulmonary clinics. The company participates in major medical conferences including the American Association for Thoracic Surgery (AATS) and American Thoracic Society (ATS).

Artera is an AI-powered precision oncology company developing multimodal artificial intelligence (MMAI) platforms that analyze digital pathology and clinical data to provide personalized cancer treatment recommendations. The company operates a CLIA-certified laboratory in Jacksonville, Florida, delivering laboratory-developed tests (LDTs) for cancer risk stratification and treatment guidance. ArteraAI Prostate Test, the company's flagship offering, received FDA De Novo Authorization as Software as a Medical Device (SaMD), making it the first and only AI test recommended in NCCN Clinical Practice Guidelines for Prostate Cancer. The test provides risk stratification for early-stage prostate cancer patients and predicts which NCCN Intermediate-risk patients will benefit from short-term androgen-deprivation therapy with radiation. The Prostate Test analyzes existing H&E histopathology slides without additional staining, delivers results within 1–2 days, demonstrates consistent performance across diverse populations, and is covered by Medicare and many commercial insurers. Artera also offers the ArteraAI Breast Cancer Test, providing 5- and 10-year distant metastasis risk assessment for early-stage breast cancer and identifies node-negative patients 50+ years old who may benefit from chemotherapy. The platform has been validated across dozens of large randomized phase III clinical trials. Artera maintains headquarters in Los Altos, California, with clinical laboratory operations in Jacksonville, Florida.

NeuraSignal is a medical technology company specializing in advanced transcranial Doppler (TCD) ultrasound systems enhanced through robotics, artificial intelligence, and cloud computing. Founded in 2013 and based in Los Angeles, the company develops FDA-cleared intelligent ultrasound platforms designed to automate and improve cerebral hemodynamics assessment for stroke detection, patent foramen ovale (PFO) screening, and vasospasm monitoring. The NG2 Intelligent Ultrasound system uses robotic control and machine learning algorithms to automatically locate the temporal window and lock onto cerebral blood flow signals with accuracy comparable to expert sonographers, while eliminating operator variability. The NeuraSignal Platform provides cloud connectivity enabling remote access, real-time data collaboration, and advanced analytics for clinical decision-making. Their portable Lucid™ TCD systems support both clinical deployment in hospital settings and international research initiatives. The technology is particularly valued in comprehensive stroke centers and neuroscience programs for its noninvasive nature, painless administration, and superior detection rates—clinical data demonstrates 3× shunt detection rates and 2.7× detection of intervenable shunts compared to standard transthoracic echocardiography (TTE).

Planet DDS is a cloud-based dental software provider headquartered in Irvine, California, serving over 13,000 dental practices across North America with a user base exceeding 60,000. Founded in 2003, the company specializes in scalable enterprise solutions for dental support organizations (DSOs), dental groups, and multi-location practices through its proprietary DentalOS™ operating system. The platform comprises integrated modules: Denticon (practice management), Cloud 9 (orthodontic-specific PM), Apteryx (cloud-based 2D/3D dental imaging with AI), Planet DDS Pay (integrated payment processing), and MyTooth (patient engagement). Solutions address core operational needs including appointment scheduling, digital imaging management, patient communication, integrated payments, revenue cycle management, and clinical documentation with AI-powered voice charting. The company targets DSOs and enterprise dental organizations seeking cloud infrastructure to reduce IT overhead, improve HIPAA compliance, and achieve operational efficiency and scalability.

Carlsmed is a publicly traded medical technology company specializing in AI-enabled personalized spine surgery solutions. The company's flagship aprevo® platform integrates artificial intelligence and 3D printing technology to design custom titanium spinal implants and deliver detailed, patient-specific surgical plans. The platform includes 3D surgical planning and visualization (myaprevo®), personalized procedural protocols, and biomechanically optimized implants designed to promote fusion. FDA-cleared for lumbar and cervical spinal fusion procedures, Carlsmed has completed over 50 cases. The company targets the substantial U.S. market opportunity of approximately 445,000 annual lumbar spine fusion procedures. With strong clinical evidence foundation and ISO 13485 certification, Carlsmed is expanding internationally following its July 2025 IPO.

Fovia, Inc. is a leading provider of cloud-based, vendor-neutral AI visualization and advanced medical imaging software solutions. The company develops F.A.S.T.® aiCockpit® and F.A.S.T.® AI SDK—flagship products that enable radiologists and clinicians to efficiently access and interact with AI results directly within their existing PACS, reporting software, and hospital systems without launching external viewers. Fovia's comprehensive product suite includes F.A.S.T.® AI Annotation, F.A.S.T.® AI Validation, F.A.S.T.® AI Workflows, F.A.S.T.® Interactive AI, and F.A.S.T.® Interactive Segmentation, providing OEMs and enterprises with tools for annotation, validation, modification, segmentation, and AI result management in 2D and 3D. The platform consolidates multi-vendor AI algorithm results into a single unified interface, streamlining radiology workflows and reducing integration complexity. With over 20 years of radiology integration experience, Fovia offers flexible deployment options (floating web application, embedded browser, widget mode, or SDK implementation) and supports seamless integration across diverse platforms and operating systems for both clinical and research applications.

Invivoscribe is a San Diego-based molecular diagnostics company founded in 1995, specializing in precision oncology testing and personalized molecular medicine for hematologic malignancies. The company develops and manufactures CE-marked in vitro diagnostic assays, research-use-only (RUO) assays, analyte-specific reagents (ASRs), and DNA/RNA controls under ISO 13485 design control. Core product lines include next-generation sequencing (NGS) panels for clonality testing (B- and T-cell), minimal residual disease (MRD) assays (LymphTrack®, LeukoStrat® FLT3-ITD and NPM1), and companion diagnostics (CDx) for precision oncology drug therapies. Invivoscribe operates LabPMM®, a CAP-accredited clinical laboratory with multiparametric flow cytometry and molecular testing services, serving clinical laboratories, pharmaceutical companies, and researchers across 160+ countries and 700+ laboratories worldwide. The company also provides bioinformatics software, custom assay development, and turn-key CDx collaboration for pharmaceutical partners, emphasizing regulatory expertise and streamlined drug approval pathways.

Hologic, Inc. is a global medical technology company founded in 1985, headquartered in Redwood City, California, that specializes in diagnostics, surgical, and medical imaging technologies focused on women's health. The company develops and manufactures innovative platforms for the detection, diagnosis, and treatment of health conditions affecting women across all life stages, with particular expertise in breast health and cancer screening. Hologic's portfolio includes advanced mammography systems with integrated AI-powered detection technology, diagnostic devices, and surgical solutions. The company holds over 4,100 patents and operates in 36 countries with approximately 7,000 employees. Hologic's technology platforms emphasize early detection and proactive treatment to improve clinical outcomes and raise the standard of care globally. The company maintains regulatory compliance through FDA approvals and international certifications. In 2025, Hologic was acquired by Blackstone and TPG, becoming a privately held company. Hologic serves hospitals, imaging centers, diagnostic laboratories, and healthcare systems worldwide, with particular focus on women's preventive health, oncology, and reproductive health markets.

Ceevra is a medical software company that develops FDA-cleared machine learning and computer vision algorithms to generate detailed, interactive 3D digital models from CT and MRI imaging studies. The platform automatically processes imaging data without requiring manual input from hospital personnel and delivers 3D surgical visualization accessible on mobile devices, tablets, laptops, and integrated surgical robotic displays. Ceevra's 3D models are clinically validated to improve surgical planning and patient outcomes across multiple surgical specialties including thoracic, urologic, gynecologic, and general/hepatopancreaticobiliary (HPB) surgery. The solution supports open, laparoscopic, and robotic-assisted surgical approaches. Clinical evidence published in JAMA Network Open demonstrates significant improvements in surgical outcomes, including enhanced cancer control, functional preservation, and reduced adjuvant therapy rates in robotic urologic procedures. Ceevra serves major U.S. healthcare systems including UCLA Health, Mayo Clinic affiliates, Memorial Sloan Kettering, Baptist Health South Florida, and Tulane University School of Medicine. The company operates on a subscription model with implementation designed for rapid deployment across hospital networks.

Invenio Imaging, Inc. develops and commercializes the NIO Laser Imaging System, a stimulated Raman histology (SRH) platform that enables rapid, label-free tissue imaging for intraoperative pathology assessment. The NIO system delivers high-quality histological images in under 3 minutes without requiring tissue staining or sectioning, allowing on-site evaluation by surgical and pathology staff. The platform features the NIO Slide sample preparation module and integrates natively with existing hospital IT infrastructure via DICOM interfaces for digital image sharing and archiving. Invenio Imaging also offers NIO Glioma Reveal, a deep learning–based image analysis algorithm for identifying cancer infiltration in glioma surgery; this product has received CE Mark approval in the European Union and is available for research use only in the United States. The company serves multiple surgical specialties including neurosurgery, interventional pulmonology, urology, ENT, breast oncology, GI endoscopy, organ transplantation, and nephrology. The technology preserves tissue viability for downstream molecular and genetic analysis, enabling pathologists to conduct additional studies on the same specimen. The NIO platform has exceeded 2,000 installed systems globally and is supported by clinical evidence from leading academic medical centers including NYU Langone Health and University of Freiburg.

Visage Imaging GmbH is a software company specializing in enterprise imaging platforms and Picture Archiving and Communication Systems (PACS). The company develops Visage 7, a cloud-engineered, server-side platform designed for fast medical image interpretation and diagnostic workflow optimization. Visage 7 is marketed as the industry's first cloud-native PACS architecture offering near-immediate access to imaging data with 100% real-time multi-dimensional reconstructions. Key capabilities include ultrafast speed, unified multi-modality imaging with native clinical tools, and seamless integration of AI diagnostics. The platform supports both on-premise and cloud-based SaaS deployment models. Visage Ease Pro™, an FDA 510(k) cleared iOS/iPadOS mobile application, enables remote image interpretation across all diagnostic modalities except mammography. The company also offers the Visage AI Accelerator program, bridging research and clinical imaging with unified diagnostics. Reported clinical outcomes include up to 50% increased reading efficiency, 23% increased CT utilization, and implementation timelines up to 300% faster than legacy systems. The platform supports complete PACS operations with dynamic data migration from single or multiple legacy PACS systems during implementation. Visage serves hospital health systems, imaging centers, and radiological organizations globally, with demonstrated deployments in North America and Europe.

Avatar Medical USA Inc develops FDA-cleared and CE-marked 3D medical imaging visualization software that transforms DICOM medical images into interactive 3D patient avatars for clinical consultation, surgical planning, and medical education. The platform is hardware-agnostic and integrates with existing PACS systems without preprocessing requirements. It enables real-time 3D visualization suitable for multiple surgical specialties including neurosurgery, oncology, ENT, oral maxillofacial surgery, cardiovascular and vascular surgery, and urology. The software supports intraoperative guidance, multidisciplinary team collaboration, and patient engagement during pre- and post-operative consultations. Avatar Medical also offers Eonis Vision, a consultation-focused product, and Avatar Medical Academy for medical education. The platform supports extended reality (XR) interaction for immersive visualization. Clinical applications span from patient communication and informed consent to detailed surgical planning and training environments. The company serves major teaching hospitals and medical centers across North America and Europe, including Assistance Publique-Hôpitaux de Paris, Sorbonne University, and University of Miami.

Illuminant Surgical develops real-time surgical navigation systems using artificial intelligence, computer vision, and dynamic projection mapping to enhance image-guided procedures. The company's flagship product, Skylight™, is a non-invasive anatomical projection system designed for spine surgery and interventional access procedures. Skylight projects imaging directly onto the patient's anatomy, eliminating the cognitive burden of traditional navigation systems that require surgeons to mentally translate 2D scans into 3D spatial awareness while constantly shifting attention between screens and the surgical field. The system employs SkinMatch™ patient registration technology to streamline workflow integration into any procedure room with minimal training (one day) and setup time (minutes rather than 30+ minutes). Illuminant Surgical addresses a critical gap in surgical technology by making advanced navigation accessible beyond major medical centers—scaling the solution to ambulatory surgical centers, private specialty clinics, and pain management facilities. The company's technology reduces operational friction, decreases OR costs, and expands treatment capacity. As of the website content, Skylight has not received FDA clearance and is not available for commercial use. The company is led by co-founders listed in Forbes 30 Under 30 Healthcare and is advised by prominent clinical and engineering leaders from USC Spine Center, Stanford Biodesign, and Stanford Medical Mixed Reality Lab, as well as business advisors including the founder of Masimo and former Stryker executive.